Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
出版年份 2020 全文链接
标题
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
作者
关键词
-
出版物
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-04-28
DOI
10.1111/jgh.15078
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues
- (2019) Tetsuya Hosaka et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir
- (2019) Jung Hwan Yu et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Long-Term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection
- (2019) Hye Won Lee et al. Clinical Gastroenterology and Hepatology
- The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
- (2019) Zeyu Zhang et al. BMC CANCER
- A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea
- (2019) Seung Up Kim et al. JOURNAL OF HEPATOLOGY
- External validation of the modified PAGE ‐B score in Asian chronic hepatitis B patients receiving antiviral therapy
- (2019) Hye Won Lee et al. LIVER INTERNATIONAL
- Minimal increases of serum alpha‐fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy
- (2019) Alessandro Loglio et al. LIVER INTERNATIONAL
- High Level of Hepatitis B Core-related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
- (2019) Tai-Chung Tseng et al. GASTROENTEROLOGY
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea
- (2018) Jung Hwan Yu et al. HEPATOLOGY RESEARCH
- Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
- (2018) Yao-Chun Hsu et al. JOURNAL OF HEPATOLOGY
- Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study
- (2018) Mindie H Nguyen et al. JOURNAL OF INFECTIOUS DISEASES
- Mortality, liver transplantation, and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir
- (2018) Byung Gyu Kim et al. JOURNAL OF VIRAL HEPATITIS
- Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir
- (2018) Yao-Chun Hsu et al. JOURNAL OF VIRAL HEPATITIS
- A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir
- (2018) Hung-Hsien Chiang et al. LIVER INTERNATIONAL
- Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
- (2018) HyunPhil Shin et al. Saudi Journal of Gastroenterology
- Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy
- (2018) Ji Hyun Kim et al. JOURNAL OF HEPATOLOGY
- Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B
- (2018) Grace Lai-Hung Wong et al. JOURNAL OF HEPATOLOGY
- The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B
- (2018) Byung Gyu Kim et al. LIVER INTERNATIONAL
- Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B
- (2018) Jonggi Choi et al. JAMA Oncology
- Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B
- (2018) Yao-Chun Hsu et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
- (2017) George V. Papatheodoridis et al. HEPATOLOGY
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score
- (2017) W. P. Brouwer et al. JOURNAL OF VIRAL HEPATITIS
- Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study
- (2017) S.-Y. Li et al. JOURNAL OF VIRAL HEPATITIS
- Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir
- (2017) Mi Na Kim et al. LIVER INTERNATIONAL
- Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
- (2017) Chien-Hung Chen et al. Oncotarget
- Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study
- (2016) Joseph Ahn et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment
- (2016) Jung Hee Kim et al. HEPATOLOGY
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
- (2016) George Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013
- (2016) Jeffrey D Stanaway et al. LANCET
- Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
- (2016) Tung-Hung Su et al. LIVER INTERNATIONAL
- Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis
- (2015) Y. C. Chen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
- (2015) W. Ray Kim et al. CANCER
- Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis
- (2015) Anna S.F. Lok et al. HEPATOLOGY
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
- (2015) S. K. Sarin et al. Hepatology International
- Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
- (2015) George V. Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy
- (2014) C. S. Coffin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis
- (2014) Soon Sun Kim et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
- (2014) Pauline Arends et al. GUT
- Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B
- (2014) Y.-C. Hsu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection
- (2014) Ryoko Yamada et al. JOURNAL OF GASTROENTEROLOGY
- Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
- (2014) G. V. Papatheodoridis et al. JOURNAL OF VIRAL HEPATITIS
- Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting
- (2014) R. Idilman et al. JOURNAL OF VIRAL HEPATITIS
- Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate
- (2014) Kayla M. Atkinson et al. Research Synthesis Methods
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
- (2013) Grace Lai-Hung Wong et al. HEPATOLOGY
- Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus–Related Cirrhosis
- (2012) Seyfettin Köklü et al. Clinical Gastroenterology and Hepatology
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
- (2012) Tetsuya Hosaka et al. HEPATOLOGY
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- (2012) Patrick Marcellin et al. LANCET
- Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
- (2011) Hwai-I Yang et al. LANCET ONCOLOGY
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
- (2010) Ting-Tsung Chang et al. HEPATOLOGY
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
- (2007) Giovanna Fattovich et al. JOURNAL OF HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started